Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3.

Article  CAS  PubMed  Google Scholar 

de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92(1):86–95.

Article  PubMed  Google Scholar 

James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain. 2016;139(11):2983–93.

Article  PubMed  PubMed Central  Google Scholar 

Irwin KE, Sheth U, Wong PC, Gendron TF. Fluid biomarkers for amyotrophic lateral sclerosis: a review. Mol Neurodegener. 2024;19(1):9.

Article  PubMed  PubMed Central  Google Scholar 

Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta PR, Brown AL, Ward ME, Fratta P. The era of cryptic exons: implications for ALS-FTD. Mol Neurodegener. 2023;18(1):16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seddighi S, Qi YA, Brown A-L, Wilkins OG, Bereda C, Belair C, et al. Mis-spliced transcripts generate de novo proteins in TDP-43–related ALS/FTD. Sci Transl Med. 2024;16(734):eadg7162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Irwin KE, Jasin P, Braunstein KE, Sinha IR, Garret MA, Bowden KD et al. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD. Nat Med. 2024:1–12.

Calliari A, Daughrity LM, Albagli EA, Castellanos Otero P, Yue M, Jansen-West K, et al. HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases. Mol Neurodegeneration. 2024;19(1):29.

Article  CAS  Google Scholar 

Feng W, Beer JC, Hao Q, Ariyapala IS, Sahajan A, Komarov A, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14(1):7238.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 2022;14(628):eabi9196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Estades Ayuso V, Pickles S, Todd T, Yue M, Jansen-West K, Song Y, et al. TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains. Mol Neurodegeneration. 2023;18(1):57.

Article  CAS  Google Scholar 

Agra Almeida Quadros AR, Li Z, Wang X, Ndayambaje IS, Aryal S, Ramesh N, et al. Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer’s disease. Acta Neuropathol. 2024;147(1):9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung M, Carter EK, Veire AM, Dammer EB, Chang J, Duong DM, et al. Cryptic exon inclusion is a molecular signature of LATE-NC in aging brains. Acta Neuropathol. 2024;147(1):29.

Article  CAS  PubMed  PubMed Central  Google Scholar